About: Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 26 October 2009

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2009 (ast) наукова стаття, опублікована в жовтні 2009 (uk) scientific article published on 26 October 2009 (en) مقالة علمية نشرت في 26 أكتوبر 2009 (ar)
publication date	wds:Q37474061-24F21403-6E9E-434D-B561-5CE8E43FF0F7
publication date	2009-10-26 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37474061-45144D5F-3494-4547-84A2-2CDDBBFA7540
language of work or name	English
cites work	wds:Q37474061-225DAD85-8A09-4C6E-8C64-0E4F412EA74E wds:Q37474061-253FF821-3896-44C6-B897-7EC53B08C464 wds:Q37474061-325333F4-09DA-43D6-9EC3-EB05C3FDF41A wds:Q37474061-3C6E6902-D08A-4EF4-B840-FC90A426BECB wds:Q37474061-3EA7A48C-2DCB-4927-A550-4D27C967E34B wds:Q37474061-4A0EADE4-1CCF-4282-B8A8-277CA47F5B70 wds:Q37474061-52508B7B-AF0B-4F36-817C-8D84AC037703 wds:Q37474061-64D67AE9-027E-49ED-B76F-0B60B3EDE309 wds:Q37474061-81CF9364-8FB7-4D72-B750-345389076B38 wds:Q37474061-8A5EA732-9EB9-4AC4-A0E4-7EB72D1FF7D6 wds:Q37474061-8B2B039D-BC42-4A83-ACDC-BAE461B3893D wds:Q37474061-8D7829FD-FDAB-4DBD-8044-F7D093B4B0FF wds:Q37474061-92D5C6AD-F1CD-43AF-95E4-B10760F38C06 wds:Q37474061-A7289632-44CD-4824-9D62-AA37257E04A4 wds:Q37474061-A7503A17-350B-4BDF-BD4D-A8A06DB7E0B9 wds:Q37474061-B99A38AA-52E4-4DFD-B933-009FFAE6113E wds:Q37474061-B9F38D74-FF1A-4790-9221-70D90A265FDD wds:Q37474061-CB4DBBFA-0752-4BFF-8FBA-A83092F429E8 wds:Q37474061-CE997B7D-D0F0-447C-86F3-39767680114B wds:Q37474061-EB3D6D98-BFCE-4023-A4DD-E45E4EF79702
cites work	Cancer statistics, 2008 Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy
author name string	wds:Q37474061-0B8CFB93-8DCE-4FED-82D5-0FDBC9A56B63 wds:Q37474061-10DAD02E-0AA2-44ED-A7D7-7E2B9871FE06 wds:Q37474061-56294DB4-DEF3-46C3-8EAD-E213A46FB8F7 wds:Q37474061-5998E58D-C29C-476B-A721-BAC87ECF1F8A wds:Q37474061-6CEBDCDB-E3B4-4F97-BF40-AA1A502B79D8 wds:Q37474061-879FF740-2227-440E-81F9-F500E6B0C457 wds:Q37474061-8BCC5642-45EF-4E95-9F94-220FC4B0FF2F wds:Q37474061-93220979-715B-458F-B1E0-3290F3997101 wds:Q37474061-CBD7440F-D77C-41C7-B3BA-AFC419F9E117 wds:Q37474061-FAD94F50-9001-4593-B365-952728971107
author name string	Matthew H Kulke Richard M Goldberg Robert J Mayer Peter C Enzinger Hedy L Kindler Donna Niedzwiecki Margaret A Tempero Donna R Hollis Michael Cusnir Stefan M Gorsch
rdfs:label	Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. (en) Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. (nl) Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. (ast)
skos:prefLabel	Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. (en) Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. (nl) Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. (ast)
name	Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. (en) Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. (nl) Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. (ast)
title	wds:Q37474061-EE8E80DA-5EEF-42B3-8166-47CEAA05EE7A
title	Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. (en)
page(s)	wds:Q37474061-7353E222-B326-4B65-8729-8CAC87604810
page(s)	5506-5512
instance of	wds:Q37474061-59F0067C-8AE8-4774-BEB5-5A685E6D3C55
instance of	scholarly article
main subject	wds:Q37474061-4ACA964D-4C93-4A82-AE4E-E9C3121DCDEE wds:Q37474061-4E402513-73F8-47EB-A8EA-D0BA3222604D wds:Q37474061-5161E019-D0DB-4E8A-B616-C3C0CCC93C7E wds:Q37474061-A15AB3E9-AB78-4B5B-A40B-82C119DF5145

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software